CA2448300A1 - Process for preparing sertraline intermediates - Google Patents
Process for preparing sertraline intermediates Download PDFInfo
- Publication number
- CA2448300A1 CA2448300A1 CA002448300A CA2448300A CA2448300A1 CA 2448300 A1 CA2448300 A1 CA 2448300A1 CA 002448300 A CA002448300 A CA 002448300A CA 2448300 A CA2448300 A CA 2448300A CA 2448300 A1 CA2448300 A1 CA 2448300A1
- Authority
- CA
- Canada
- Prior art keywords
- dichlorophenyl
- dihydro
- sertraline
- solvent
- methanamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/86—Separation
- C07C209/88—Separation of optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A pharmaceutical intermediate, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine, which can be used in the production of sertraline hydrochloride, is conveniently prepared by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone with monomethylamine in a solvent which is an amide solvent with a structure of general formula (IV), wherein R1, R3 are indepen dently hydrogen or C1-6 alkyl, which can be substituted, and R2 is hydrogen.
Description
PROCESS FOR PREPARING SERTRALINE INTERMEDIATES
The present invention relates to a novel method for the production of sertraline. The present invention also relates to a novel process for the preparation of a pharmaceutical intermediate, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine.
BACKGROUND OF THE INVENTION
N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1 (2H)-naphtalenylidene]-methanamine of formula I
N
I
CI
CI
is a well known pharmaceutical intermediate which can be used e.g. in the preparation of sertraline, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, which has a structure of formula II
HN
/ I I
~CI
CI
The present invention relates to a novel method for the production of sertraline. The present invention also relates to a novel process for the preparation of a pharmaceutical intermediate, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine.
BACKGROUND OF THE INVENTION
N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1 (2H)-naphtalenylidene]-methanamine of formula I
N
I
CI
CI
is a well known pharmaceutical intermediate which can be used e.g. in the preparation of sertraline, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, which has a structure of formula II
HN
/ I I
~CI
CI
Sertraline is marketed in the form of its hydrochloride for the treatment of depression, obsessive-compulsive disorder and panic disorder.
The synthesis of sertraline is described in U.S. Patent no. 4,536,518. The process described includes a condensation reaction of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone of formula III
O
III
-CI
CI
with monomethylamine, which is catalyzed by titanium tetrachloride yielding N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine. The reaction is an equilibrium reaction, where the equilibrium has to be shifted.
This can be done e.g. by using titanium tetrachloride to remove water from the reaction mixture. Titanium tetrachloride, however, is extremely reactive with water and side products formed are hazardous, and therefore other dehydrating agents have been considered.
Another route to N-4-[3,4-dichlorophenyl)-3,4-dihydro-1 (2H)-naphtalenylidene]methanamine is described in U.S. Patent No. 4,855,500, wherein the dehydration characteristics of appropriate mesh molecular sieves are employed to remove water from the reaction mixture to promote the condensation reaction between 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone and monomethylamine. Molecular sieves are expensive and they must typically be regenerated if they are to be reused.
In a process described in EP 1 059 287 (+) enantiomer of sertraline is prepared by either of the processes described above using (+) enantiomer of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone as a starting material, so that no resolution of the final product is needed.
Still another route to to N-4-[3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine is described in the patent application WO
99/36394.
In the process described the condensation reaction of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone with monomethylamine is performed in an alcohol solvent. The solubility of the reaction product to the solvent is such that the equilibrium is favorably enhanced towards the product. No catalysts or dehydrating agents are needed. However, monomethylamine is easily vaporized in reaction temperatures (about 50 deg C or above) and therefore a suitable pressure rated vessel is needed and the reaction is carried out under pressure.
Sertraline hydrochloride is produced by further hydrogenating the N-4-[3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine resulted from processes above and resolving the racemic mixture and finally crystallizing sertraline hydrochloride.
Now we have surprisingly found, that if the solvent for the imination process is selected from the solvents of the invention, the reaction can be performed in atmospheric pressure and ambient temperature. Also the amount of the solvent needed is low, impurities are not formed and the yield is good. Water removal agents like titanium tetrachloride or molecular sieves are not needed.
Another aspect of this invention relates to the process wherein the imine product formed in the process of the invention is hydrogenated to form sertraline which is further resolved by e.g. mandelic acid and finally crystallized as (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
Still another aspect of the invention is a pharmaceutical composition comprising (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
The synthesis of sertraline is described in U.S. Patent no. 4,536,518. The process described includes a condensation reaction of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone of formula III
O
III
-CI
CI
with monomethylamine, which is catalyzed by titanium tetrachloride yielding N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine. The reaction is an equilibrium reaction, where the equilibrium has to be shifted.
This can be done e.g. by using titanium tetrachloride to remove water from the reaction mixture. Titanium tetrachloride, however, is extremely reactive with water and side products formed are hazardous, and therefore other dehydrating agents have been considered.
Another route to N-4-[3,4-dichlorophenyl)-3,4-dihydro-1 (2H)-naphtalenylidene]methanamine is described in U.S. Patent No. 4,855,500, wherein the dehydration characteristics of appropriate mesh molecular sieves are employed to remove water from the reaction mixture to promote the condensation reaction between 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone and monomethylamine. Molecular sieves are expensive and they must typically be regenerated if they are to be reused.
In a process described in EP 1 059 287 (+) enantiomer of sertraline is prepared by either of the processes described above using (+) enantiomer of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone as a starting material, so that no resolution of the final product is needed.
Still another route to to N-4-[3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine is described in the patent application WO
99/36394.
In the process described the condensation reaction of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenone with monomethylamine is performed in an alcohol solvent. The solubility of the reaction product to the solvent is such that the equilibrium is favorably enhanced towards the product. No catalysts or dehydrating agents are needed. However, monomethylamine is easily vaporized in reaction temperatures (about 50 deg C or above) and therefore a suitable pressure rated vessel is needed and the reaction is carried out under pressure.
Sertraline hydrochloride is produced by further hydrogenating the N-4-[3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphtalenylidene]methanamine resulted from processes above and resolving the racemic mixture and finally crystallizing sertraline hydrochloride.
Now we have surprisingly found, that if the solvent for the imination process is selected from the solvents of the invention, the reaction can be performed in atmospheric pressure and ambient temperature. Also the amount of the solvent needed is low, impurities are not formed and the yield is good. Water removal agents like titanium tetrachloride or molecular sieves are not needed.
Another aspect of this invention relates to the process wherein the imine product formed in the process of the invention is hydrogenated to form sertraline which is further resolved by e.g. mandelic acid and finally crystallized as (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
Still another aspect of the invention is a pharmaceutical composition comprising (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
DESCRIPTION OF THE INVENTION
In a first embodiment, the present invention provides a process for producing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine, by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone with monomethylamine in a solvent selected from the a group consisting of amide solvents of general formula IV:
R2~0 IV
wherein R1 and R3 are independently hydrogen or C1_6 alkyl, which can be substituted, and R2 is hydrogen.
In another embodiment, the present invention provides a process wherein the N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine so formed in the process of the invention is hydrogenated to form sertraline which may be further resolved by the use of, e.g., mandelic acid and finally crystallized as ( 1 S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
In still another embodiment, the present invention provides a pharmaceutical composition comprising (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
In a preferred embodiment of the present invention the solvent used in the imination step is dimethylformamide or methylformamide, most preferably, the solvent is dimethylformamide.
The imination of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone with monomethylamine may be performed in the presence of acid catalyst, which can be any suitable organic or inorganic acid, e.g., formic acid, acetic acid, sulfonic acid, or hydrochloric acid. In a preferred embodiment of the invention, formic acid or 5 acetic acid is used as the acid catalyst.
The solubility of the product in the solvent of the invention is low, so that the product is slowly crystallizing out of the reaction mixture and it can be isolated easily by, e.g., filtration. The process has also considerable purification capacity.
The reaction can be performed under atmospheric pressure and is typically carried out at a temperature in the range of from about 0 °C to about 50 °C, preferably at ambient temperature, i.e., from about 15 °C to. about 25 °C. Of course, the imination may also be carried out under a slight positive pressure of an inert atmosphere, such as nitrogen gas or argon gas.
Suitably, the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone is added to the solvent in an amount of about 300 g to about 400 g per liter of solvent, preferably about 320 g to about 350 g per liter of solvent. The methylamine is added in an amount of about 4 mole to about 6 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone, preferably about 4.8 mole to about 5.2 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone. When used, the acid catalyst is typically added to the mixture in an amount of about 0.1 mole to about 2.0 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone, preferably about 0.4 mole to about 0.6 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone.
The present method is not constrained to any particular order of addition, and the reaction may be conveniently performed by charging all of the components into a suitable-size vessel at 0 °C and then allowing the reaction mixture to rise to ambient temperature. The reaction mixture is then stirred at ambient temperature for a time of about 10 to about 30 hours, preferably about 20 to about 24 hours. If desired, the progress of the reaction may be monitored by any suitable technique, including chromatography, especially high-pressure liquid chromatography (HPLC) or thin-layer chromatography (TLC).
In a first embodiment, the present invention provides a process for producing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine, by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone with monomethylamine in a solvent selected from the a group consisting of amide solvents of general formula IV:
R2~0 IV
wherein R1 and R3 are independently hydrogen or C1_6 alkyl, which can be substituted, and R2 is hydrogen.
In another embodiment, the present invention provides a process wherein the N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine so formed in the process of the invention is hydrogenated to form sertraline which may be further resolved by the use of, e.g., mandelic acid and finally crystallized as ( 1 S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
In still another embodiment, the present invention provides a pharmaceutical composition comprising (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
In a preferred embodiment of the present invention the solvent used in the imination step is dimethylformamide or methylformamide, most preferably, the solvent is dimethylformamide.
The imination of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone with monomethylamine may be performed in the presence of acid catalyst, which can be any suitable organic or inorganic acid, e.g., formic acid, acetic acid, sulfonic acid, or hydrochloric acid. In a preferred embodiment of the invention, formic acid or 5 acetic acid is used as the acid catalyst.
The solubility of the product in the solvent of the invention is low, so that the product is slowly crystallizing out of the reaction mixture and it can be isolated easily by, e.g., filtration. The process has also considerable purification capacity.
The reaction can be performed under atmospheric pressure and is typically carried out at a temperature in the range of from about 0 °C to about 50 °C, preferably at ambient temperature, i.e., from about 15 °C to. about 25 °C. Of course, the imination may also be carried out under a slight positive pressure of an inert atmosphere, such as nitrogen gas or argon gas.
Suitably, the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone is added to the solvent in an amount of about 300 g to about 400 g per liter of solvent, preferably about 320 g to about 350 g per liter of solvent. The methylamine is added in an amount of about 4 mole to about 6 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone, preferably about 4.8 mole to about 5.2 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone. When used, the acid catalyst is typically added to the mixture in an amount of about 0.1 mole to about 2.0 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone, preferably about 0.4 mole to about 0.6 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone.
The present method is not constrained to any particular order of addition, and the reaction may be conveniently performed by charging all of the components into a suitable-size vessel at 0 °C and then allowing the reaction mixture to rise to ambient temperature. The reaction mixture is then stirred at ambient temperature for a time of about 10 to about 30 hours, preferably about 20 to about 24 hours. If desired, the progress of the reaction may be monitored by any suitable technique, including chromatography, especially high-pressure liquid chromatography (HPLC) or thin-layer chromatography (TLC).
The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-I(2H)-naphthalenylidene]methanamine is insoluble in the reaction solvent and exists as a solid precipitate in the reaction mixture at the completion of the reaction. The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-I (2H)-naphthalenylidene]methanamine may then be isolated from the reaction mixture by any suitable solid-liquid separation technique, such as filtration, centrifugation, or decantation.
The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine may be further hydrogenated to form cis-(1S)(1R)- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine which may then be optically resolved with, e.g., mandelic acid and finally crystallized to afford (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
Pharmaceutical compositions comprising ( 1 S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or its pharmaceutically suitable salt prepared by the method of the invention can be prepared by methods well-known in the art.
The following examples are used to illustrate 'but by no means to limit the scope of the invention, which is defined in the claims.
EXAMPLE 1.
Preparation of N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenylidene]-methanamine 4-(3,4-Dichlorophenyl)-3,4-dihydro-1-(2H)-naphtalenone (100 g), N,N-dimethylformamide (300 ml) and formic acid (6.5 ml) are charged. Methylamine (56.0 g) is added at about 0 °C. The mixture is stirred~for~ 20 hours at room temperature. The mixture is cooled to 10 °C and stirred for I hour. The crystalline compound is filtered and washed with methanol.,The yield is 97.7 g (93.5 %) as dried.
The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine may be further hydrogenated to form cis-(1S)(1R)- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine which may then be optically resolved with, e.g., mandelic acid and finally crystallized to afford (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
Pharmaceutical compositions comprising ( 1 S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or its pharmaceutically suitable salt prepared by the method of the invention can be prepared by methods well-known in the art.
The following examples are used to illustrate 'but by no means to limit the scope of the invention, which is defined in the claims.
EXAMPLE 1.
Preparation of N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenylidene]-methanamine 4-(3,4-Dichlorophenyl)-3,4-dihydro-1-(2H)-naphtalenone (100 g), N,N-dimethylformamide (300 ml) and formic acid (6.5 ml) are charged. Methylamine (56.0 g) is added at about 0 °C. The mixture is stirred~for~ 20 hours at room temperature. The mixture is cooled to 10 °C and stirred for I hour. The crystalline compound is filtered and washed with methanol.,The yield is 97.7 g (93.5 %) as dried.
The same process was performed using N-methylformamide as a solvent in the imination step. Yield was 90.1 %.
EXAMPLE 2.
Preparation of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride (sertraline hydrochloride) N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1 (2H)-naphthalenylidene]-methanamine (50 g) is hydrogenated over palladium on charcoal to yield cis-(1S)(1R)- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine.
The rasemic compound is resolved by mandelic acid and finally crystallized as sertraline hydrochloride. The total yield from 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphtalenone is 67 % (of the theoretical (+)-enantiomer).
EXAMPLE 2.
Preparation of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride (sertraline hydrochloride) N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1 (2H)-naphthalenylidene]-methanamine (50 g) is hydrogenated over palladium on charcoal to yield cis-(1S)(1R)- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine.
The rasemic compound is resolved by mandelic acid and finally crystallized as sertraline hydrochloride. The total yield from 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphtalenone is 67 % (of the theoretical (+)-enantiomer).
Claims (8)
1. A process for preparing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine of formula I:
said process comprising:
(1) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone of formula III:
with monomethylamine in a solvent which is selected from the group consisting of amide solvents with a structure of general formula IV:
wherein R1 and R3 are independently hydrogen or C1-6 alkyl, which can be substituted and R2 is hydrogen.
said process comprising:
(1) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone of formula III:
with monomethylamine in a solvent which is selected from the group consisting of amide solvents with a structure of general formula IV:
wherein R1 and R3 are independently hydrogen or C1-6 alkyl, which can be substituted and R2 is hydrogen.
2. A process according to claim 1 wherein the solvent is dimethylformamide or methylformamide.
3. A process according to claim 2 wherein the solvent used is dimethylformamide.
4. A process according to any of claims 1 to 3 wherein the reaction is performed in the presence of an acid catalyst.
5. A process according to any of claim 4 wherein the acid catalyst is formic acid or acetic acid.
6. A process according to any of claims 1 to 5 wherein the reaction is performed in the temperature range from about 0 deg C to about 50 deg C.
7. A process for producing (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or pharmaceutically acceptable salt thereof, which has the structure of formula II:
said process comprising:
(1) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone of formula III:
with monomethylamine in a solvent which is selected from the group consisting of amide solvents with a structure of general formula IV:
wherein R1 and R3 are independently hydrogen or C1-6 alkyl, which can be substituted and R2 is hydrogen to obtain N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]-methanamine of formula I:
(2) hydrogenating said N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine of formula I to obtain a mixture of racemic cis sertraline and racemic trans sertraline, and (3) resolving said mixture of racemic cis sertraline and racemic trans sertraline to obtain said (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or pharmaceutically acceptable salt thereof.
7. A process for producing (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or pharmaceutically acceptable salt thereof, which has the structure of formula II:
said process comprising:
(1) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone of formula III:
with monomethylamine in a solvent which is selected from the group consisting of amide solvents with a structure of general formula IV:
wherein R1 and R3 are independently hydrogen or C1-6 alkyl, which can be substituted and R2 is hydrogen to obtain N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]-methanamine of formula I:
(2) hydrogenating said N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine of formula I to obtain a mixture of racemic cis sertraline and racemic trans sertraline, and (3) resolving said mixture of racemic cis sertraline and racemic trans sertraline to obtain said (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or pharmaceutically acceptable salt thereof.
7. A process according to claim 6 wherein the mixture of racemic cis sertraline and racemic trans sertraline is resolved by mandelic acid.
8. A process of claim 6 or 7 wherein said pharmaceutically acceptable salt is hydrochloride.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29426601P | 2001-05-31 | 2001-05-31 | |
US60/294,266 | 2001-05-31 | ||
FI20011146A FI20011146A0 (en) | 2001-05-31 | 2001-05-31 | New manufacturing method |
FI20011146 | 2001-05-31 | ||
PCT/FI2002/000466 WO2002096860A1 (en) | 2001-05-31 | 2002-05-30 | Process for preparing sertraline intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2448300A1 true CA2448300A1 (en) | 2002-12-05 |
Family
ID=26161179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002448300A Abandoned CA2448300A1 (en) | 2001-05-31 | 2002-05-30 | Process for preparing sertraline intermediates |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1397342A1 (en) |
CA (1) | CA2448300A1 (en) |
WO (1) | WO2002096860A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200808115T1 (en) * | 2006-04-28 | 2009-03-23 | Sandoz Ag | Process for the Preparation of 4 (S, R) - (3,4-dichlorophenyl) -3,4-dihydro-1 (2H) -naphthalen-1-ylidene] methylamine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU222341B1 (en) * | 1996-12-18 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Process for producing sertraline and intermediate used in this process |
IN191358B (en) * | 1998-01-16 | 2003-11-29 | Pfizer Prod Inc | |
US6593496B1 (en) * | 1999-06-09 | 2003-07-15 | Pfizer Inc | Process for preparing sertraline from chiral tetralone |
IN185109B (en) * | 1999-09-01 | 2000-11-18 | Torrent Pharmaceuticals Ltd | |
CA2388814A1 (en) * | 1999-11-16 | 2001-05-25 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of ketimines |
ES2245652T3 (en) * | 1999-11-16 | 2006-01-16 | Ciba Specialty Chemicals Holding Inc. | PROCEDURE FOR THE PREPARATION OF CETIMINAS. |
IL150332A0 (en) * | 1999-12-21 | 2002-12-01 | Teva Pharma | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
-
2002
- 2002-05-30 CA CA002448300A patent/CA2448300A1/en not_active Abandoned
- 2002-05-30 EP EP02727626A patent/EP1397342A1/en not_active Withdrawn
- 2002-05-30 WO PCT/FI2002/000466 patent/WO2002096860A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2002096860A1 (en) | 2002-12-05 |
EP1397342A1 (en) | 2004-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6552227B2 (en) | Process for preparing (+)-cis-sertraline | |
US6593496B1 (en) | Process for preparing sertraline from chiral tetralone | |
AU2001243634A1 (en) | Novel process for preparing (+)-cis-sertraline | |
CN1990455A (en) | Simple and novel process for preparing indenes derivatives | |
KR100362788B1 (en) | Novel process for preparing a ketimine | |
WO2001016089A1 (en) | A process for the preparation of cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride | |
CA2448300A1 (en) | Process for preparing sertraline intermediates | |
US20030013768A1 (en) | Process for the production of sertraline and intermediates useful therefor | |
US7173153B2 (en) | Sertraline hydrochloride form II and methods for the preparation thereof | |
US7728147B2 (en) | Detomidine hydrochloride crystallization method | |
US6723878B2 (en) | Method for preparing sertraline | |
US20080275252A1 (en) | Atipamezole Hydrochloride Crystallization Method | |
WO2005007611A2 (en) | Process for the preparation of an imine intermediate | |
CH654295A5 (en) | PROCESS FOR THE PREPARATION OF 3,3'- OR 3,4'-DIAMINODIPHENYLMETHANE. | |
AU2006201492A1 (en) | Novel process for preparing (+)-cis-sertraline | |
WO2007071421A1 (en) | An improved process for the preparation of sertraline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |